Author's response to reviews

Title: Progression of lower and higher-order aberrations: a longitudinal study

Authors:

Balamurali Vasudevan (drmurali@gmail.com)
Brian Fisher (b.fisher@midwestern1.edu)
Barry Case (b.case@midwestern1.edu)
Phu Lam (plam@midwestern1.edu)
Jeff Wayman (jwayman@midwestern1.edu)

Version: 4 Date: 11 December 2014

Author's response to reviews: see over
Editor’s comments:

(1) Lines 123 - 131: highlighted material belongs in the Results section (e.g., moved to lines 180 et seq).
Reply: These changes have been made in the manuscript.

(2) Requesting for Copy-Edit
- We recommend that you ask a native English speaking colleague to help you copyedit the paper. If this is not possible, you may need to use a professional language editing service. For authors who wish to have the language in their manuscript edited by a native-English speaker with scientific expertise, BioMed Central recommends Edanz (www.edanzediting.com/bmc1). BioMed Central has negotiated a 10% discount to the fee charged to BioMed Central authors by Edanz. Use of an editing service is neither a requirement nor a guarantee of acceptance for publication. For more information, see our FAQ on language editing services at http://www.biomedcentral.com/authors/authorfaq/editing.
Reply: This manuscript has been reviewed and the language is now improved.

(3) Requesting for Email-add
- Please provide email address of each co-authors in the Title page of the manuscript PDF file.
Reply: These changes have been made in the manuscript.

(4) Competing Interest
- Please be advised that manuscripts must include a ?Competing interests? section. This should be placed after the Conclusions/Abbreviations. If there are none to declare, please include the statement ?The authors declare that they have no competing interests.? Please consider the following questions and include an appropriate declaration of competing interests in your manuscript:
Reply: No competing interest. These changes have been made in the manuscript.

Financial competing interests
? In the past five years have you received reimbursements, fees, funding, or salary from an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future? Is such an organization financing this manuscript (including the article-processing charge)? If so, please specify.
Reply: None. These changes have been made in the manuscript.

? Do you hold any stocks or shares in an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future? If so, please specify.
Reply: None. These changes have been made in the manuscript.
? Do you hold or are you currently applying for any patents relating to the content of the manuscript? Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript? If so, please specify.
Reply: None. These changes have been made in the manuscript.

? Do you have any other financial competing interests? If so, please specify.
Reply: None. These changes have been made in the manuscript.

Non-financial competing interests
? Are there any non-financial competing interests (political, personal, religious, ideological, academic, intellectual, commercial or any other) to declare in relation to this manuscript? If so, please specify.
Reply: None. These changes have been made in the manuscript.

For more information please visit the instructions for authors on the journal’s website.

(5) Acknowledgments
- By way of a section ‘Acknowledgments’, please acknowledge anyone who contributed towards the article by making substantial contributions to conception, design, acquisition of data, or analysis and interpretation of data, or who was involved in drafting the manuscript or revising it critically for important intellectual content, but who does not meet the criteria for authorship. Please also include the source(s) of funding for each author, and for the manuscript preparation. Authors must describe the role of the funding body, if any, in design, in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. Please also acknowledge anyone who contributed materials essential for the study. If a language editor has made significant revision of the manuscript, we recommend that you acknowledge the editor by name, where possible. The role of a scientific (medical) writer must be included in the acknowledgements section, including their source(s) of funding. We suggest wording such as 'We thank Jane Doe who provided medical writing services on behalf of XYZ Pharmaceuticals Ltd.'
Authors should obtain permission to acknowledge from all those mentioned in the Acknowledgments section.

- Please note that if you don’t have someone to acknowledge, we would still need you to provide an Acknowledgments section within the manuscript and you may also mention there that you do not have someone to acknowledge to.
Reply: Yes. These changes have been made in the manuscript.

(6) Please change the Contribution Statement to Author’s Contribution.
Reply: Yes. These changes have been made in the manuscript.
(7) Requesting for consent statement

- Please state in the Methods section whether written informed consent for participation in the study was obtained from participants or, where participants are children, a parent or guardian.

Reply: Yes. These changes have been made in the manuscript.